Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced new positive AOC 1001 data demonstrating improvement in multiple additional functional endpoints and favorable long-term safety and…
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) and Seagen Inc. (Nasdaq: SGEN) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in combination with KEYTRUDA® (pembrolizumab)…
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing, and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that a Phase I study of the best-in-class anti-CD24 antibody, ATG-031,…
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® (sotorasib) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). These…
Vitestro starts largest-scale clinical trial globally for its autonomous blood drawing device, with enrolment of first patients in A.D.O.P.T.
Vitestro, expert in medical robotics, has launched the A.D.O.P.T. Trial for its autonomous blood drawing device (image). With an anticipated sample size of over 10,000 patients, this is the most significant study globally to date of autonomous blood collection. Vitestro…
Chemotherapy before surgery reduces risk of colon cancer recurrence, finds Cancer Research UK-funded trial
Administering chemotherapy before surgery can significantly reduce the risk of colon cancer recurrence, according to a Cancer Research UK-funded trial. The FOxTROT trial, led by the University of Birmingham and the University of Leeds, involved 1,053 colon cancer patients from…
Decentralized Clinical Trial to Test Revolutionary Migraine Treatment Device
Mi-Helper, a non-invasive neuromodulation device, is set to revolutionize the treatment of migraines, a condition that affects an estimated one billion people worldwide. Developed by Mi-Helper, Inc., the small device delivers a controlled stream of conditioned air with a nebulized…
NGS commences pilot clinical trial with a sports supplement for children
Nutritional Growth Solutions, Ltd., (NGS, ASX:NGS), a leading provider of clinically backed nutritional products designed for children, announces the launch of its clinical study to evaluate the effect of its innovative sports supplement on the physical activity performance of young…
